Jazz Pharmaceuticals (JAZZ) Stock Price, News & Analysis

$108.32
-1.35 (-1.23%)
(As of 04/24/2024 ET)
Today's Range
$107.60
$109.39
50-Day Range
$107.10
$132.77
52-Week Range
$106.61
$146.70
Volume
401,278 shs
Average Volume
608,323 shs
Market Capitalization
$6.82 billion
P/E Ratio
17.70
Dividend Yield
N/A
Price Target
$195.08

Jazz Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
80.1% Upside
$195.08 Price Target
Short Interest
Bearish
5.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.66mentions of Jazz Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$1.44 M Bought Last Quarter
Proj. Earnings Growth
14.72%
From $16.24 to $18.63 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.85 out of 5 stars

Medical Sector

32nd out of 907 stocks

Pharmaceutical Preparations Industry

12th out of 421 stocks

JAZZ stock logo

About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

JAZZ Stock Price History

JAZZ Stock News Headlines

Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
Jazz Pharmaceuticals plc (JAZZ)
Jazz Pharmaceuticals: Cheap But Complicated
Biden replacement revealed?
A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
Jazz Pharmaceuticals: Cancer and the Combination Approach
Cancer and the Combination Approach
The Analyst Landscape: 12 Takes On Jazz Pharmaceuticals
JAZZ Apr 2024 110.000 put
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/24/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
Employees
2,800
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$195.08
High Stock Price Target
$230.00
Low Stock Price Target
$131.00
Potential Upside/Downside
+80.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$414.83 million
Pretax Margin
7.77%

Debt

Sales & Book Value

Annual Sales
$3.83 billion
Cash Flow
$27.70 per share
Book Value
$59.36 per share

Miscellaneous

Free Float
60,228,000
Market Cap
$6.82 billion
Optionable
Optionable
Beta
0.59

Social Links

7 Stocks to Own Before the 2024 Election Cover

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

JAZZ Stock Analysis - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" JAZZ shares.
View JAZZ analyst ratings
or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price target for 2024?

13 brokers have issued 12-month price targets for Jazz Pharmaceuticals' shares. Their JAZZ share price targets range from $131.00 to $230.00. On average, they anticipate the company's stock price to reach $195.08 in the next twelve months. This suggests a possible upside of 80.1% from the stock's current price.
View analysts price targets for JAZZ
or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2024?

Jazz Pharmaceuticals' stock was trading at $123.00 on January 1st, 2024. Since then, JAZZ shares have decreased by 11.9% and is now trading at $108.32.
View the best growth stocks for 2024 here
.

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our JAZZ earnings forecast
.

How can I listen to Jazz Pharmaceuticals' earnings call?

Jazz Pharmaceuticals will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) announced its quarterly earnings results on Wednesday, February, 28th. The specialty pharmaceutical company reported $4.40 EPS for the quarter, missing the consensus estimate of $4.44 by $0.04. The specialty pharmaceutical company earned $1.01 billion during the quarter, compared to analysts' expectations of $1.01 billion. Jazz Pharmaceuticals had a net margin of 10.82% and a trailing twelve-month return on equity of 31.27%.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of 18.150-19.350 for the period, compared to the consensus EPS estimate of 19.940. The company issued revenue guidance of $4.0 billion-$4.2 billion, compared to the consensus revenue estimate of $4.1 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Polaris Capital Management LLC (2.27%), Perpetual Ltd (0.75%), Los Angeles Capital Management LLC (0.32%), Sumitomo Mitsui Trust Holdings Inc. (0.25%), Centre Asset Management LLC (0.11%) and Kovack Advisors Inc. (0.09%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Peter Gray, Philip L Johnson, Renee D Gala, Rick E Winningham, Robert Iannone and Samantha Pearce.
View institutional ownership trends
.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
This page (NASDAQ:JAZZ) was last updated on 4/24/2024 by MarketBeat.com Staff

From Our Partners